MPX-RESPONSE
An international EU-funded program advancing mpox research for better outbreak preparedness
Initiated with the 2022-2023 mpox global outbreak, MPX-RESPONSE was designed to contribute to some of key challenges with mpox:
- a better understanding of the epidemiology and the transmission modes
- the need for curative treatments validated through rigorous, large-scale protocols
With 3 randomized trials (UNITY, MOSA, EPOXI) and one large observational cohort (MOSAIC), the program will produce robust data at a global scale.
MPX-RESPONSE consortium has been built on the experience of existing networks and the expertise of international platforms.
The project goes beyond the scientific state-of-the-art and aims to enhance Europe’s capacity to provide a rapid international response to a global epidemic.
UNITY
A phase III, multi-country, randomized, placebo-controlled, double-blinded trial to evaluate the safety and efficacy of tecovirimat (SIGA) for the treatment of adult patients with mpox virus disease.
Coordinated and sponsored by ANRS MIE
Geographical coverage: International (Argentina, Brazil, Switzerland)
MOSA
A phase III, multi-country, randomized, placebo-controlled, double-blinded trial to assess the efficacy and safety of brincidofovir (Emergent BioSolutions) against mpox in mpox endemic regions.
Coordinated and sponsored by PANTHER
Geographical coverage: Sub-Saharan African countries (endemic mpox regions)
EPOXI
A phase III multi-country randomized, placebo-controlled, double-blinded trial to evaluate the safety and efficacy of tecovirimat (SIGA) for the treatment of adult patients with mpox disease.
Coordinated by Ecraid and with UMCU as scientific sponsor
Geographical coverage: Europe
MOSAIC
An European, multi-country, randomized, observational cohorte study to describe clinical and virologic characteristics and outcomes of participants with laboratory confirmed clade IIb mpox infection.
Coordinated and sponsored by the University of Oxford, with ANRS MIE as sponsor representative in Europe
Geographical coverage: Europe
